VaxartVaxart reports mixed PhII data for norovirus vaccine; J&J to proceed with Cidara influenza deal
07 Sep 2023
Clinical ResultPhase 2Vaccine
Vaxart announced on Wednesday that a Phase II study of its oral norovirus vaccine achieved the primary endpoint of reducing the rate of infection. The vaccine is designed to go after the norovirus GI.1 genotype, which causes gastroenteritis.
However, in the trial’s other primary endpoint, the vaccine achieved a 21% reduction in norovirus acute gastroenteritis, which was not statistically significant against the placebo. VaxartVaxart is planning to analyze the Phase II data further. — Tyler Patchen
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.